CytoMed Therapeutics (FRA:F98) Payments of Debt: €-0.04 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:F98 CytoMed Therapeutics Ltd FRA:F98
19 GF Score
Price €0.76
! 2 Warning Signs
View Full Analysis

What is CytoMed Therapeutics Payments of Debt?

CytoMed Therapeutics FRA:F98 -9.58% 19 Payments of Debt is €-0.04 Mil as of Dec. 2025. GuruFocus rates FRA:F98 with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

CytoMed Therapeutics's Payments of Debt for the six months ended in Dec. 2025 was €-0.02 Mil.

CytoMed Therapeutics's Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.04 Mil.

CytoMed Therapeutics Payments of Debt Related Terms

CytoMed Therapeutics Payments of Debt Historical Data

* Premium members only.

The historical data trend for CytoMed Therapeutics's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoMed Therapeutics Payments of Debt Chart

CytoMed Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial -0.04 -0.54 -0.44 -0.03 -0.04

CytoMed Therapeutics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 -0.01 -0.02 -0.02 -0.02
FRA:F98
19GF Score
CytoMed Therapeutics Ltd FRA:F98
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytoMed Therapeutics Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of €-0.04 Mil mean?
CytoMed Therapeutics (FRA:F98) has a Payments of Debt of €-0.04 Mil as of Dec. 2025. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on CytoMed Therapeutics and its competitors.
Is CytoMed Therapeutics' Payments of Debt too high?
CytoMed Therapeutics' current Payments of Debt is €-0.04 Mil. Overall, CytoMed Therapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does CytoMed Therapeutics' Payments of Debt compare to LEXX and INAB?
CytoMed Therapeutics' Payments of Debt of €-0.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on CytoMed Therapeutics and its competitors. CytoMed Therapeutics's current Payments of Debt is €-0.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoMed Therapeutics stock overvalued right now?
CytoMed Therapeutics (FRA:F98) has a current Payments of Debt of €-0.04 Mil. The current Payments of Debt is €-0.04 Mil. CytoMed Therapeutics' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For CytoMed Therapeutics (FRA:F98), the current Payments of Debt is €-0.04 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CytoMed Therapeutics Business Description

Other Exchanges GDTC:USA
Address 1 Commonwealth Lane, No. 08-22 One Commonwealth, Singapore, SGP, 149544
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
19GF Score

Get the complete analysis for FRA:F98

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.76
Price